Nanobiotix

Nanobiotix is a leading nanomedicine company that intends to revolutionize radiotherapy, making it m

NANOBIOTIX, pioneer and leader in nanomedicine, has developed a revolutionary concept dedicated to the local treatment of cancer. NANOBIOTIX is focused on the development of NanoXray, a pipeline of patented products, which are based on the physical mechanism of action of the nanoparticles interacting with X-rays and maximizing radiation effect into tumor cells. NanoXray products enhance the effica

cy of the radiotherapy in the tumor without increasing healthy tissues damages. NanoXray products can be used with existing standard radiation equipments available in almost every hospital world-wide.

28/09/2017

Nanobiotix shortlisted for People's Choice Award at IR Magazine Global Forum ! We count on your support !

Please click the link to complete this form.

28/09/2017

Nanobiotix plans to conduct its 1st clinical trial in combination in the US: NBTXR3 w/ immune checkpoint inhibitors

07/02/2017

Nanobiotix appoints senior executive from pharmaceutical industry, as Chief Operating Officer http://bit.ly/2kNcm0A

14/11/2016

Nanobiotix Nanobiotix presents NBTXR3 preclinical data demonstrating its potential usage as in situ vaccine for cancer at the Society for Immunotherapy of Cancer Annual Meeting http://bit.ly/2ewpntq

14/09/2016

Nanobiotix announces submission for first market approval of lead product NBTXR3 in Europe http://bit.ly/2cpgsHh

22/04/2016

It's the homestretch for Nanobiotix to be the 2016! We still need your vote! http://bit.ly/1Teqt7T

Vote for the Buzz of BIO! Vote for your favorite innovative biotech company in the Pipelines of Promise and Technologies of Tomorrow categories. One vote per person, per day will be strictly enforced. See contest rules. The companies with the most votes in each category will win one complimentary Co…

17/11/2014

NANOBIOTIX honored at the INVESTOR AWARDS 2013 in the “Young Talent” category http://bit.ly/16K9Muj

Paris, France, 7 November, 2013 – NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of

17/11/2014

Retrouvez la Lettre aux actionnaires n°1 de Nanobiotix icihttp://www.nanobiotix.eu/wp-content/files_mf/1390403867Nanobiotix_newlsetter_1_novembre2013.pdf

17/11/2014

Nanobiotix obtient un financement de 2,8 M€ de bpifrance
(ex OSEO) pour accélérer le développement de son produit
leader NBTXR3 dans une nouvelle indication http://bit.ly/1cRpweg

Through ETPN (European Technology Platform of Nanomedicine), Nanobiotix is driving nanomedicine in Europe and is now involved in the first nanomedicine

26/06/2013

Nanobiotix: selection of NBTX-IV and collaboration with the for development http://bit.ly/19B2XuM

Characterization studies to be undertaken by the US National Cancer Institute’s Nanotechnology Characterization Laboratory Paris, France, 26 June, 2013 –

Adresse

60, Rue De Wattignies
Paris
75012

Site Web

http://www.nanobiotix.com/

Notifications

Soyez le premier à savoir et laissez-nous vous envoyer un courriel lorsque Nanobiotix publie des nouvelles et des promotions. Votre adresse e-mail ne sera pas utilisée à d'autres fins, et vous pouvez vous désabonner à tout moment.